Hypothalamic-pituitary-adrenocortical axis: neuropsychiatric aspects

Area of Science:

• Neuroendocrinology
• Psychiatry
• Biomarker Discovery

Background:

• Aberrant hypothalamic-pituitary-adrenocortical (HPA) axis activity is observed in numerous psychiatric disorders.
• HPA hormones are of significant interest as potential biomarkers for disease diagnosis and treatment response.
• HPA axis dysregulation presents differently across conditions, including elevated, reactive, or low activity patterns.

Purpose of the Study:

• To review the evidence for HPA axis activity in psychiatric disorders.
• To explore the impact of psychotropic medications on HPA function.
• To assess the utility of HPA measures in predicting relapse and treatment outcomes.

Main Methods:

• Literature review of studies investigating HPA axis activity in psychiatric populations.
• Analysis of HPA hormone levels in relation to specific diagnoses (e.g., depression, anxiety, schizophrenia, PTSD).
• Examination of the effects of antidepressants, mood stabilizers, and antipsychotics on HPA function.

Main Results:

• HPA activity is elevated in melancholic depression, panic disorder, OCD, and schizophrenia.
• HPA axis reactivity to stress is increased in social anxiety disorder and autism spectrum disorders.
• HPA activity is often low in PTSD and atypical depression; medication effects on HPA activity vary.

Conclusions:

• HPA axis measures are most reliably used to predict relapse likelihood in psychiatric disorders.
• Changes in HPA activity may contribute to the clinical benefits of psychiatric treatments.
• Addressing patient heterogeneity and standardizing HPA assessment are crucial for future clinical applications.